Business & Tech

Spero Therapeutics announces $51.7 million in new financing

Cambridge-based Spero Therapeutics, a biopharmaceutical company that develops treatments for antibiotic-resistant bacterial infections, has raised $51.7 million in new capital.

The funding round was led by corporate venture capital firm GV, formerly known as Google Ventures. RA Capital Management and Rock Springs Capital also participated in the Series C financing.


CEO Ankit Mahadevia, MD, said the money will be used for clinical trials.

“One [asset] in particular that we’d highlight is the Potentiator platform, which takes existing antibiotics and adds [the] ability to treat multi-drug resistance to those antibiotics,” Mahadevia said.

Get Talking Points in your inbox:
An afternoon recap of the day’s most important business news, delivered weekdays.
Thank you for signing up! Sign up for more newsletters here

The announcement follows a report from the World Health Organization listing the 12 families of antibiotic-resistant bacteria that pose the greatest threat to human health.

“Each pathogen on that list is addressed by a member of our pipeline,” Mahadevia said.

Shelby Grebbin can be reached at
Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
You're reading  1 of 5 free articles.
Get UNLIMITED access for only 99¢ per week Subscribe Now >
You're reading1 of 5 free articles.Keep scrolling to see more articles recomended for you Subscribe now
We hope you've enjoyed your 5 free articles.
Continue reading by subscribing to for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of
Marketing image of